Background
Goals
The primary goal of this UZGent sponsored clinical trial is to investigate the efficacy of sargramostim (Leukine®, Partner therapeutics), a growth factor that is known for its beneficial effects in viral pneumonia in the improvement of oxygenation. Moreover, this project will also look at the short –and long-term outcome of patients treated with Leukine®.
Facts & Figures
Thematic area
Epidemic control
Novel molecular insights and treatment options in COVID-19 patients to guide treatment of progressed disease stages, with a particular focus on patients with reduced blood oxygenation levels.
Funding
- Downstream molecular analysis
- Setup clinical trial
- Study medication
Promotor
Partners
VIB-UGent
VIB-UGent-UZ Gent
UGent-UZ Gent
Contribution to the project
To study the effect of Leukine® on immune functioning, monocytes and dendritic cells obtained from blood samples from patients will be characterized. In addition, cytokine and chemokine levels will also be investigated (IRC) and single cell RNA will be sequenced (IRC).
Expected impact
This forerunner trial sponsored by UZGent will greatly aid in the understanding of -and fight against- SARS-CoV-2. One of the expected outcomes is halting disease progression from early acute hypoxic respiratory failure to acute respiratory distress syndrome (ARDS). This could alleviate the pressure on ICU units during the current and future outbreaks.
Prof. Bart Lambrecht underscores the importance of this trial: “Patients with COVID-19 who progress to acute hypoxic respiratory failure due to COVID-19 have very limited treatment options and a high mortality rate. We rapidly initiated clinical trials to investigate treatment options that provide the stimulus to restore immune homeostasis in the lungs and can promote lung repair mechanisms.”
Contact
